Tan Wei Shen, Berg Sebastian, Cole Alexander P, Krimphove Marieke, Marchese Maya, Lipsitz Stuart R, Nabi Junaid, Sammon Jesse D, Choueiri Toni K, Kibel Adam S, Sun Maxine, Chang Steven, Trinh Quoc-Dien
JNCI Cancer Spectr. 2019 Feb 1;3(1):pkz003. doi: 10.1093/jncics/pkz003. eCollection 2019 Mar.
Despite randomized data demonstrating better overall survival favoring radical nephrectomy, partial nephrectomy continues to be the treatment of choice for low-stage renal cell carcinoma.
We utilized the National Cancer Database to identify patients younger than 50 years diagnosed with low-stage renal cell carcinoma (cT1) treated with radical nephrectomy or partial nephrectomy (2004-2007). Inverse probability of treatment weighting adjustment was performed for all preoperative factors to account for confounding factors. Kaplan-Meier curves and Cox proportional hazards regression analyses were used to compare overall survival of patients in the two treatment arms. Sensitivity analysis was performed to explore the interaction of type of surgery and clinical stage on overall survival.
Among the 3009 patients (median age = 44 years [interquartile range (IQR) = 40-47 years]), 2454 patients (81.6%) were treated with radical nephrectomy and 555 patients (18.4%) with partial nephrectomy. The median follow-up was 108.6 months (IQR = 80.2-124.3 months) during which 297 patients (12.1%) in the radical nephrectomy arm and 58 patients (10.5%) in the partial nephrectomy arm died. Following inverse probability of treatment weighting adjustment, there was no difference in overall survival between patients treated with partial nephrectomy and radical nephrectomy (hazard ratio = 0.83, 95% confidence interval = 0.63 to 1.10, = .196). There were no statistically significant interactions between type of surgery and clinical stage on treatment outcome.
There was no difference in long-term overall survival between radical and partial nephrectomy in young and healthy patients. This patient cohort may have sufficient renal reserve over their lifetime, and preserving nephrons by partial nephrectomy may be unnecessary.
尽管随机数据表明根治性肾切除术能带来更好的总生存期,但对于低分期肾细胞癌,部分肾切除术仍是首选治疗方法。
我们利用国家癌症数据库,确定了2004年至2007年间诊断为低分期肾细胞癌(cT1)且接受根治性肾切除术或部分肾切除术的50岁以下患者。对所有术前因素进行治疗权重逆概率调整,以考虑混杂因素。采用Kaplan-Meier曲线和Cox比例风险回归分析比较两个治疗组患者的总生存期。进行敏感性分析以探讨手术类型和临床分期对总生存期的相互作用。
在3009例患者中(中位年龄 = 44岁[四分位间距(IQR)= 40 - 47岁]),2454例患者(81.6%)接受了根治性肾切除术,555例患者(18.4%)接受了部分肾切除术。中位随访时间为108.6个月(IQR = 80.2 - 124.3个月),在此期间,根治性肾切除组有297例患者(12.1%)死亡,部分肾切除组有58例患者(10.5%)死亡。经过治疗权重逆概率调整后,部分肾切除术和根治性肾切除术患者的总生存期无差异(风险比 = 0.83,95%置信区间 = 0.63至1.10,P = 0.196)。手术类型和临床分期在治疗结果上无统计学显著的相互作用。
年轻健康患者接受根治性肾切除术和部分肾切除术的长期总生存期无差异。该患者队列在其一生中可能有足够的肾储备,因此通过部分肾切除术保留肾单位可能没有必要。